Zoe P. Klein

The paper examines therapy-associated mutagenesis at CTCF binding sites across 4,870 tumor genomes, finding increased mutation enrichment at these sites under radiotherapy and trifluridine treatment.

The paper identifies mutational signatures in cancer genomes that alter protein sequence motifs in signaling networks, linking mutation etiology to functional consequences.

The paper identifies TOP2B binding sites as mutational hotspots in cancer genomes, showing their role in structural variants and driver mutations in genes like TP53 and MYC.

The paper identifies immunogenomic interactions across 13 cancer types using a multi-omics framework, linking genomic alterations and immune features to patient survival.

The paper introduces DPM, a directional integration method for multi-omics data that identifies consistent gene and pathway changes across datasets and highlights inconsistent evidence.